National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 4 of 4 Research Studies DisplayedWang L, Rouse B, Marks-Anglin A
Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.
The purpose of this study was to test rapid approaches that use Drugs@FDA (a public database of approved drugs) and ClinicalTrials.gov to identify trials and to compare these two sources with bibliographic databases as an evidence base for a systematic review and network meta-analysis (NMA). The investigators concluded that a rapid NMA approach using data from Drugs@FDA was feasible but had its own limitations. They asserted that reporting of trial design and results can be improved in both the drug approval packages and on ClinicalTrials.gov.
AHRQ-funded; HS024788.
Citation: Wang L, Rouse B, Marks-Anglin A .
Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.
J Clin Epidemiol 2019 Oct;114:84-94. doi: 10.1016/j.jclinepi.2019.06.010..
Keywords: Medication, Research Methodologies, Evidence-Based Practice
Desai RJ, Wyss R, Abdia Y
Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching - a plasmode simulation study.
Bootstrapping can account for uncertainty in propensity score (PS) estimation and matching processes in 1:1 PS-matched cohort studies. While theory suggests that the classical bootstrap can fail to produce proper coverage, practical impact of this theoretical limitation in settings typical to pharmacoepidemiology is not well studied. In a plasmode-based simulation study, the investigators compared performance of the standard parametric approach, which ignores uncertainty in PS estimation and matching, with two bootstrapping methods.
AHRQ-funded; HS022193.
Citation: Desai RJ, Wyss R, Abdia Y .
Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching - a plasmode simulation study.
Pharmacoepidemiol Drug Saf 2019 Jun;28(6):879-86. doi: 10.1002/pds.4784..
Keywords: Research Methodologies, Patient-Centered Outcomes Research, Medication
Dunn AG, Orenstein L, Coiera E
The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics.
The purpose of this study was to determine whether certain trial characteristics are associated with faster or more frequent inclusion in systematic reviews for drug interventions in type 2 diabetes. Results showed that time to inclusion was shorter for trials with industry funding, more participants, and published in higher impact factor journals, while frequency of inclusion was greater for trials with industry funding, more participants, positive conclusions, and published in higher impact factor journals.
AHRQ-funded; HS024798.
Citation: Dunn AG, Orenstein L, Coiera E .
The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics.
J Clin Epidemiol 2019 May;109:62-69. doi: 10.1016/j.jclinepi.2019.01.009..
Keywords: Diabetes, Medication, Research Methodologies
Desai K, Carroll I, Asch S
Extremely large outlier treatment effects may be a footprint of bias in trials from less developed countries: randomized trials of gabapentinoids.
This meta-analyses looked at extremely large outlier treatment effects for clinical trials of gabapentinoids conducted in less developed countries. Researchers identified 10 meta-analyses that showed statistically significant favorable findings. In four meta-analyses, heterogeneity estimates exceeded 90% for postoperative pain. Those 4 meta-analyses showed 39 out of 77 studies with extremely favorable results and out of those 39, 33 were conducted in less developed countries with no tradition of favorable research, 22 reported no information on funding, and 20 reported no conflicts of interest. Conversely, 27 of 38 studies with unfavorable results came from developed countries.
AHRQ-funded; HS024096.
Citation: Desai K, Carroll I, Asch S .
Extremely large outlier treatment effects may be a footprint of bias in trials from less developed countries: randomized trials of gabapentinoids.
J Clin Epidemiol 2019 Feb;106:80-87. doi: 10.1016/j.jclinepi.2018.10.012..
Keywords: Medication, Research Methodologies